The role of the bile acid chenodeoxycholic acid in the targeted oral delivery of the anti-diabetic drug gliclazide, and its applications in type 1 diabetes. (17th August 2016)

• Record Type: Journal Article
• Authors: Mathavan, Sangeetha; Chen-Tan, Nigel; Arfuso, Frank; Al-Salami, Hani
• Is Part Of: Artificial cells, nanomedicine, and biotechnology. Volume 44:Number 6(2016)
• Page Start: 1508
• Page End: 1519
• Publication Date: 2016-08-17
• Subjects: artificial cell microencapsulation -- bile acids -- chenodeoxycholic acid -- diabetes -- gliclazide; Artificial cells -- Periodicals; Nanotechnology -- Periodicals; Blood substitutes -- Periodicals; Tissue engineering -- Periodicals; Molecules -- Periodicals; Biotechnology -- Periodicals; 615.39
• DOI: 10.3109/21691401.2015.1058807
• Languages: English
• ISSNs: 2169-1401

Abstract

Abstract : Gliclazide (G) is used to treat type 2 diabetes (T2D), and also has anti-platelet, anti-radical, and anti-inflammatory effects. G has poor water solubility and high inter-individual variations in absorption, limiting its application in type 1 diabetes (T1D). The bile acid, chenodeoxycholic acid (CDCA), has permeation-enhancing effects. Sodium alginate (SA) was used to microencapsulate G and CDCA to produce control (G-SA) and test (G-CDCA-SA) microcapsules. Both microcapsules showed uniform structure, morphology, and good stability profiles. CDCA reduced G-release at pH 7.8, while G-release was negligible at lower pH values in both microcapsules. CDCA incorporation resulted in less swelling and stronger microcapsules, suggesting improved stability.